The maker of Yaz and Yasmin, has spent $1.4 billion so far to settle approximately 6,760 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT).
Chicago, IL (PRWEB) August 08, 2013
The birth control safety center at DrugRisk.com is announcing updated information for women who have taken the contraceptives Yaz or Yasmin. The maker of the drugs recently reported they have spent approximately $1.4 billion so far to settle cases alleging blood clot injuries*.
DrugRisk.com seeks to keep patients taking popular prescription drugs informed with the latest research, safety alerts, recalls and legal news. Visitors can find out if others are experiencing similar side effects and decide if they need legal advice.
The resource center has added warnings from health experts like the British Medical Journal** and FDA*** that birth control pills containing the hormone drospirenone, like Yaz and Yasmin, can increase the risk of blood clots.
Due to the number of patients who have filed a Yasmin lawsuit alleging side effects, cases were consolidated to a special federal Multi-District Litigation court in Illinois (Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois)). The latest court records still show 9,998 cases filed****.
Now, DrugRisk has learned that Bayer, the maker of Yaz and Yasmin, has spent $1.4 billion so far to settle approximately 6,760 Yaz lawsuits alleging blood clot injuries like pulmonary embolism or deep vein thrombosis (DVT)*. This amounts to over $200,000 per case.
Anyone who suffered blood clots, DVT, stroke or pulmonary embolism after taking Yaz or Yasmin is urged to contact the DrugRisk Center or speak with a lawyer about their legal options.
Due to the specialized nature of federal MDL courts, patients should seek a lawyer with experience in defective drug litigation. DrugRisk only recommends lawyers who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Bayer Stockholder’s newsletter Pg. 64, 7/31/13; stockholders-newsletter-q2-2013.bayer.com/en/bayer-stockholders-newsletter-2q-2013.pdfx
**BMJ, 10/25/11; ncbi.nlm.nih.gov/pubmed/22027398
***FDA, 10/27/11, http://www.fda.gov/downloads/Drugs/DrugSafety/UCM277384.pdf
****JPML, 7/10/13; jpml.uscourts.gov/sites/jpml/files/Pending_MDL_Dockets_By_District-July-10-2013.pdf